Business
Voyageur Pharmaceuticals Achieves Milestone in the Development of HDXBa Barium Contrast Media
(TheNewswire) Calgary, Canada – TheNewswire - September 14, 2023 - Voyag...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Achieves Milestone in the Development of HDXBa Barium Contrast Media\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Canada –\n \n \n TheNewswire -\n \n \n September 14, 2023 -\n \n \n Voyageur Pharmaceuticals Ltd\n \n \n . (\n \n \n TSXV:VM\n \n \n ) (\n \n \n USA\n \n \n : VYYRF) (\"Voyageur\" or\nthe \"Corporation\"), a provider of innovative medical imaging\nsolutions, is pleased to announce the completion of formulation and\nthe engineering for production processing for the dry powdered barium\ncontrast media product HDXBa\n \n \n TM\n \n \n . HDXBa\n \n \n TM\n \n \n is an oral\ncontrast agent for suspension used as an oral drug for use in\ndouble-contrast radiographic examinations of the esophagus, stomach,\nand duodenum. Voyageur has a Health Canada approved license for\nHDXBa\n \n \n TM\n \n \n .\n \n \n HDXBa has been formulated to meet FDA\ndrug guidelines.\n \n \n \n \n Voyageur launched its first oral contrast agent SmoothX\nto the Canadian market, and it was well received for future use. Due\nto the sole source environment in Canada for barium contrast agents,\nclients have asked Voyageur to produce a full suite of products to\nallow them to make a seamless transition to Voyageur's product line.\nIn response to client demand, Voyageur is currently working with\nAlberta Veterinarian Laboratories (\n \n \n AVL\n \n \n ) and its\nsubsidiary Solvet\n \n \n \n https://solvet.ca/\n \n \n \n , to accelerate the formulation and testing of the remaining\nproducts that the market requires to ensure supply chain security for\nour clients. AVL is currently formulating the next 3 products with\nHealth Canada licences;\n \n \n \n \n MultiXBa, MultiXs and MultiXthin\n \n \n . Upon\ncompletion of our full suite of products, Voyageur will begin\npenetrating the Canadian radiology market.\n \n \n \n \n Market Update\n \n \n \n \n The radiology pharmaceutical sector has been plagued by\nsupply chain vulnerabilities over the past few years, which has been\nconfirmed by https://www.ashpfoundation.org/. Voyageur is moving\nforward to become a fully vertically integrated radiology drug company\nby domestically producing its own minerals for radiology drugs,\nincluding barium sulfate, iodine, and carbon fullerene. Voyageur owns\n1...